Lilly reports Mounjaro and Zepbound brought in $36.5 billion in 2025
Lilly's 2025 results show tirzepatide sales climbing on higher volume and lower realized prices, with an oral GLP-1 pill now under review [1].
Eli Lilly said on Feb. 4, 2026, that its two tirzepatide brands produced $36.5 billion in revenue in 2025, helping push full-year company revenue up 45% to $65.2 billion [1].
Mounjaro brought in $22.965 billion for the year, nearly double the $11.540 billion it recorded in 2024 [1]. Zepbound, the name tirzepatide is sold under for obesity in the United States, Canada and Japan, reached $13.542 billion, up about 175% from $4.926 billion [1]. Together the two brands accounted for about 56% of Lilly's total revenue of $65.179 billion [1].
In the fourth quarter alone, Mounjaro revenue rose 110% to $7.4 billion and Zepbound rose 122% to $4.2 billion [1]. Total quarterly revenue was $19.3 billion, up 43% from $13.5 billion a year earlier [1]. Lilly said the increase reflected a 46% rise in volume, partly offset by a 5% decline from lower realized prices [1].
U.S. revenue rose 43% to $12.9 billion, with volume up 50% and realized prices down 7% [1]. Revenue outside the U.S. also rose 43%, to $6.4 billion, driven mainly by Mounjaro [1]. Lilly said the U.S. pricing declines were driven by Zepbound and Mounjaro [1].
The release does not compare the combined $36.5 billion tirzepatide figure with any other medicine, so whether it is the highest-selling drug in the world has not been established here [1].
Why it matters for patients
The results show growth coming mainly from more sales volume rather than higher prices. In the U.S., Lilly reported a 50% increase in volume and a 7% drop in realized prices for the quarter [1]. The release does not say how those price changes affect what patients pay at a pharmacy.
Lilly said it reached millions more patients in 2025 and expanded manufacturing capacity [1]. It also announced an agreement with the U.S. government to expand access to obesity medicines for millions of Americans [1]. The release does not disclose the terms of that agreement, who qualifies, when it takes effect or what patients would pay under it.
Higher sales volume is one signal of how many people are using these drugs. Lilly's release does not report the number of patients taking Mounjaro or Zepbound, so the size of that group has not been disclosed.
What happens next
Lilly issued 2026 guidance of $80 billion to $83 billion in revenue and non-GAAP earnings per share of $33.50 to $35.00 [1].
Orforglipron, an oral GLP-1, has been submitted to regulators for obesity in the U.S. and Japan and for obesity and type 2 diabetes in the European Union [1]. The release does not give expected decision dates. Lilly also said the FDA approved a Kwikpen version of tirzepatide [1]; the release does not describe when it will reach patients.
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.